Recent evidence highlights butyrate’s role as a histone deacetylase (HDAC) inhibitor that can modulate immune function and suppress tumor growth, emphasizing its potential for cancer epigenetic therapy [268]. This evidence concerns the gene HDAC9 and neoplasm.